DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But both fields have matured to the ...
Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
For the first time, doctors have treated a baby born with a rare, life-threatening genetic disorder with a gene-editing therapy scientists tailored to specifically repair his unique mutation. The baby ...
The one-off treatment highlights the promise of a new type of gene editing and the challenges of using it to treat extremely rare genetic diseases. Doctors say they constructed a bespoke gene-editing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results